LenioBio

Executive Summary

LenioBio is a German biotechnology company founded in 2017 that has developed ALiCE®, a proprietary, plant-based, cell-free protein expression platform. The technology is designed to rapidly and scalably produce complex proteins, including antibodies and membrane proteins, for research, drug development, and industrial applications. By eliminating the need for living cells, ALiCE® reduces production time and cost while enabling the synthesis of proteins that are difficult to express in traditional systems. The company's mission is to simplify biomanufacturing to accelerate the delivery of life-saving medicines, positioning itself as a key enabler in the biologics supply chain. The global market for protein expression is expanding, driven by the growth of biologics, personalized medicine, and demand for rapid development of therapies. LenioBio's platform offers distinct advantages in speed, scalability, and versatility, making it attractive for contract manufacturing organizations (CMOs) and pharmaceutical companies. The company has garnered attention from investors and partners, though it remains in a growth phase. Success will depend on securing commercial partnerships, expanding its platform capabilities, and demonstrating cost-effectiveness at industrial scale. With a strong IP portfolio and a clear value proposition, LenioBio is well-positioned to capture market share in the evolving biomanufacturing landscape.

Upcoming Catalysts (preview)

• TBDStrategic Partnership with Major Pharma70% success
• TBDSeries B Funding Round Announcement60% success
• TBDLaunch of Commercial-Scale Production Service50% success